Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375389" target="_blank" >RIV/00216208:11130/18:10375389 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064211:_____/18:W0000140

Výsledek na webu

<a href="https://doi.org/10.1080/09546634.2017.1329507" target="_blank" >https://doi.org/10.1080/09546634.2017.1329507</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/09546634.2017.1329507" target="_blank" >10.1080/09546634.2017.1329507</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients

Popis výsledku v původním jazyce

Objective: To evaluate effectivity, safety and patients&apos; adherence to benzathine penicillin G (BPG) 1,200,000 units (1.2MU) once-every-3-week intramuscularly prophylaxis for recurrent erysipelas.Methods: Patients with documented two or more erysipelas episodes in last two years who received at least one of 10 planned doses of BPG 1.2MU intramuscularly between January 2009 and December 2015 were analyzed in this retrospective study. Number of recurrences during the 30-week prophylaxis and in the 30-week follow-up period, frequency of adverse events, patients&apos; adherence to the treatment and factors associated with the recurrence were analyzed.Results: From 132 patients, 109 (82.6%) finished the 30-week prophylactic regimen successfully. The incidence of erysipelas was 8 per 100 patient-years during the prophylactic period and 28 per 100 patient-years in the follow-up period (incidence rate ratio=0.20; 95% CI: 0.05-0.34; p&lt;.01). In univariate analysis recurrence was significantly associated only with presence of any local risk factor concurrently with obesity (OR 3.40; 95% CI: 1.10-10.50; p&lt;.05).Conclusion: Benzathine penicillin G 1.2MU once every 3weeks is an effective and well-tolerated prophylaxis of recurrent erysipelas with good patient adherence to the treatment. Further studies to determine the appropriate duration of prophylaxis are necessary.

Název v anglickém jazyce

Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients

Popis výsledku anglicky

Objective: To evaluate effectivity, safety and patients&apos; adherence to benzathine penicillin G (BPG) 1,200,000 units (1.2MU) once-every-3-week intramuscularly prophylaxis for recurrent erysipelas.Methods: Patients with documented two or more erysipelas episodes in last two years who received at least one of 10 planned doses of BPG 1.2MU intramuscularly between January 2009 and December 2015 were analyzed in this retrospective study. Number of recurrences during the 30-week prophylaxis and in the 30-week follow-up period, frequency of adverse events, patients&apos; adherence to the treatment and factors associated with the recurrence were analyzed.Results: From 132 patients, 109 (82.6%) finished the 30-week prophylactic regimen successfully. The incidence of erysipelas was 8 per 100 patient-years during the prophylactic period and 28 per 100 patient-years in the follow-up period (incidence rate ratio=0.20; 95% CI: 0.05-0.34; p&lt;.01). In univariate analysis recurrence was significantly associated only with presence of any local risk factor concurrently with obesity (OR 3.40; 95% CI: 1.10-10.50; p&lt;.05).Conclusion: Benzathine penicillin G 1.2MU once every 3weeks is an effective and well-tolerated prophylaxis of recurrent erysipelas with good patient adherence to the treatment. Further studies to determine the appropriate duration of prophylaxis are necessary.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Dermatological Treatment

ISSN

0954-6634

e-ISSN

—

Svazek periodika

29

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

39-43

Kód UT WoS článku

000423855400009

EID výsledku v databázi Scopus

2-s2.0-85019681675